12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Qutenza capsaicin regulatory update

EMA said Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) withdrew an application for a label extension for Qutenza capsaicin patch to treat peripheral neuropathic pain in adults, except when pain is caused by diabetes. According to the agency, Astellas...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >